Hinge Health, known for digital physical-therapy programmes, is acquiring digestive-care company Cylinder Health for $105 million in cash, pushing into gut health.
Announced August 6, 2026 and expected to close in the third quarter, the deal pairs Hinge’s musculoskeletal (back, joint, pelvic) and migraine programmes with Cylinder’s virtual-first care for digestive conditions — from bloating and gas to IBS and inflammatory bowel disease — including courses, microbiome testing, diet plans and virtual visits.
Why gut health
Digestive conditions affect roughly 1 in 4 US adults and drive about $135 billion in annual medical spending, yet nearly 70% of US counties lack a gastroenterologist.
That last figure is the commercial argument. A shortage means long waits, travel, and many patients who never see a specialist at all — and virtual care competes against nothing rather than against an existing local service, which is a considerably easier position than displacing incumbent care.
Which conditions actually suit virtual care
The range Cylinder covers spans conditions with very different requirements, and the distinction matters for what the model can deliver.
IBS and functional digestive symptoms are well suited. Diagnosis rests largely on symptom patterns and exclusion of other causes, and management is substantially dietary and behavioural — structured elimination diets, symptom tracking, stress management. Those are delivered as well or better through an app with regular remote contact than through infrequent office visits.
Inflammatory bowel disease is different. It is a serious immune-mediated condition requiring endoscopy, imaging, laboratory monitoring and frequently immunosuppressive or biologic therapy with real risks. Virtual care can support education, adherence and symptom monitoring around that; it cannot replace it.
Framing both under one banner is commercially convenient and clinically imprecise.
The microbiome-testing question
Microbiome testing is among the listed offerings, and it warrants more scepticism than the rest of the package.
Consumer gut-microbiome tests report which bacterial species are present, and the science connecting a given composition to specific dietary recommendations for an individual remains immature. Composition varies substantially day to day and with recent diet, and there is no established healthy reference profile.
Its value in a product like this may be as much about engagement as diagnosis — a personalised-looking result increases commitment to a programme whose actual benefit comes from the structured dietary and behavioural work.
The logic of the combination
“Many people we already serve for back, joint, pelvic, and migraine care also have chronic digestive conditions,” said Hinge co-founder and CEO Daniel Perez; one analyst called it “a logical extension of the business.”
The overlap is genuine, and the underlying economics are about distribution. These companies sell to employers and health plans, and the difficult part is winning the contract, not adding a service afterwards. A vendor already embedded with a client can add a condition at low marginal cost, while a standalone digestive-care company must win each account from scratch.
Cylinder already contracts with about 100 clients covering 2 million people, including two of the three largest pharmacy-benefit managers — which is much of what $105 million buys.
The financial shape
The company expects only a modest $7–8 million boost to 2026 sales, with growth from 2027, when it plans a single integrated app combining both services with AI-driven diet and lifestyle guidance.
The consolidation pattern in digital health
This acquisition fits a broader restructuring of the employer digital-health market, driven by pressure from the buyers.
Employers accumulated point solutions through the past decade — separate vendors for diabetes, mental health, musculoskeletal care, fertility, sleep — each with its own contract, app and login. Benefits teams found the administrative burden considerable and employee uptake of any single app low.
The reaction has been demand for consolidation: fewer vendors covering more conditions through one relationship and ideally one interface. That favours larger platforms and squeezes single-condition companies, whose standalone value falls even when their clinical product is good.
Which explains both sides of this deal. Hinge is assembling the multi-condition platform buyers now want, and Cylinder — a strong single-condition business with real contracts — is worth more inside such a platform than competing against one. The planned single integrated app is the explicit expression of that logic.
Does digital care actually reduce cost?
The value proposition sold to employers is that virtual programmes lower total medical spending by preventing expensive care downstream, and the evidence for that claim is more contested than the marketing suggests.
Independent analyses of employer digital-health programmes have repeatedly found smaller savings than vendors project, and sometimes none. The recurring problem is selection: the employees who enrol tend to be more health-engaged than those who do not, so better outcomes among participants partly reflect who signed up rather than what the programme did.
Utilisation can also rise rather than fall. Making specialist access easier surfaces conditions that were previously untreated, which is good clinically and does not reduce near-term spending.
For digestive care specifically the case is plausible where virtual management genuinely substitutes for specialist visits and repeated testing in functional conditions. It is weaker where the programme adds a layer alongside the gastroenterology care patients still need.
Paying $105 million for that near-term revenue means the price reflects the client relationships and the integrated product rather than the business as it currently operates — a reasonable bet if cross-selling works, and an expensive one if it does not. Business news, not investment or medical advice.